UniProt Q9Y463 · PDB · AlphaFold · Substrate: DYRKtide · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 98.9% | 1.1% | 91.48 | 0.563 |
| 2 | Midostaurin | 94.3% | 5.7% | 78.64 | 0.500 |
| 3 | Pacritinib | 79.0% | 20.9% | 88.64 | 0.452 |
| 4 | Palbociclib | 77.1% | 22.9% | 98.75 | 0.673 |
| 5 | Defactinib | 76.1% | 23.9% | 92.68 | 0.450 |
| 6 | Alectinib | 68.5% | 31.5% | 95.49 | 0.651 |
| 7 | Brigatinib | 65.2% | 34.8% | 82.96 | 0.513 |
| 8 | Avapritinib | 47.1% | 52.9% | 97.73 | 0.644 |
| 9 | Afatinib | 44.5% | 55.5% | 98.50 | 0.709 |
| 10 | Sunitinib | 41.6% | 58.4% | 91.73 | 0.524 |
| 11 | Gilteritinib | 41.1% | 58.9% | 88.97 | 0.506 |
| 12 | Nintedanib | 35.5% | 64.5% | 90.23 | 0.608 |
| 13 | Ruxolitinib | 28.5% | 71.5% | 98.25 | 0.592 |
| 14 | Baricitinib | 25.1% | 74.9% | 97.99 | 0.616 |
| 15 | Dabrafenib | 24.6% | 75.4% | 94.74 | 0.633 |
| 16 | Netarsudil | 21.1% | 78.9% | 93.22 | 0.676 |
| 17 | Ceritinib | 18.5% | 81.5% | 95.44 | 0.618 |
| 18 | Osimertinib | 13.7% | 86.3% | 97.24 | 0.733 |
| 19 | Dacomitinib | 13.1% | 86.9% | 97.99 | 0.664 |
| 20 | Gefitinib | 12.3% | 87.7% | 99.25 | 0.650 |
Paralog block
DYRK1_DYRK1A, DYRK1B
EMT expression
- Mesenchymal log2(TPM+1): 2.52
- Epithelial log2(TPM+1): 2.47
- Fold change: 0.04
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 98.9% · KISS 36.19
- Palbociclib — inh 77.1% · KISS 27.08
- Midostaurin — inh 94.3% · KISS 24.19
Selectivity landscape vs inhibition on DYRK1B
Each point is one of the 92 approved drugs; color = inhibition % on DYRK1B.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…